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Background: The assessment of a neuropathic pain component (NePC) to establish the 
neurological criteria required to comply with the clinical description is based on history 
taking, clinical examination, and quantitative sensory testing (QST) and includes bedside 
examination (BSE). The objective of this study was to assess the potential association between 
the clinically diagnosed presence or absence of an NePC, BSE, and the Nijmegen–Aalborg 
screening QST (NASQ) paradigm in patients with chronic (≥3 months) low back and leg pain 
or with neck shoulder arm pain or in patients with chronic pain due to suspected peripheral 
nerve damage.
Methods: A total of 291 patients participated in the study. Pain (absence or presence of neuro-
pathic pain) was assessed independently by two physicians and compared with BSE (measure-
ments of touch [finger, brush], heat, cold, pricking [safety pin, von Frey hair], and vibration). 
The NASQ paradigm (pressure algometry, electrical pain thresholds, and conditioned pain 
modulation) was assessed in 58 patients to generate new insights.
Results: BSE revealed a low association of differences between patients with either absent 
or present NePC: heat, cold, and pricking sensations with a von Frey hair were statistically 
significantly less common in patients with present NePC. NASQ did not reveal any differences 
between patients with and without an NePC.
Conclusion: Currently, a standardized BSE appears to be more useful than the NASQ paradigm 
when distinguishing between patients with and without an NePC.
Keywords: quantitative sensory testing, NASQ, Nijmegen–Aalborg screening QST, clinical 
assessment, diagnostic accuracy
Introduction
Neuropathic pain is defined by the International Association for the Study of Pain 
(IASP) as “pain caused by a lesion or disease of the somatosensory nervous system”. It 
is a clinical description rather than a clinical diagnosis which would require “a demon-
strable lesion or disease that satisfies the established neurological diagnostic criteria”.1 
In the general population, 6%–8% suffer from neuropathic pain.2–4 Nociceptive pain is 
defined as “pain that arises from actual or threatened damage to non-neural tissue and 
is due to activation of nociceptors”. This allows us to distinguish between patients with 
neuropathic pain (classification based on an abnormally functioning somatosensory 
nervous system) and nociceptive pain (classification based on a normally functioning 
somatosensory nervous system). Because co-existence of both conditions (mixed-
pain condition) is frequently observed in daily clinical practice, La Cesa et al suggest 
using the presence or absence of a neuropathic pain component (absent or present 
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NePC).5 NePC assessment is based on history taking, clinical 
examination, and (quantitative) sensory testing and includes 
bedside examination (BSE).6–8 Clinical examination alone 
can never offer proof that a specific pain is of neuropathic 
origin, but it provides supporting evidence for alterations 
in the functioning of the nervous system.6 According to the 
IASP neuropathic pain special interest group (NeuPSIG), 
abnormal sensory findings should be neuroanatomically 
plausible when an NePC is present, and the sensory signs 
should be associated with the neuroanatomically plausible 
distribution compatible with an underlying relevant lesion or 
disease of the somatosensory nervous system.9,10 As part of 
a bedside clinical neurological examination, sensory testing 
can identify negative sensory symptoms such as hyperalgesia 
or hypoesthesia and/or positive sensory symptoms such as 
allodynia and hyperalgesia.5 According to Haanpää et al,6 
BSE can possibly identify where the pathology causing the 
pain can be found in the central nervous system.
In the last decades, quantitative sensory testing (QST) 
has complemented traditional neurological BSE tests. QST 
uses psychophysical tests defined as stimuli with predeter-
mined physical properties based on specific measurement 
protocols for the analysis of somatosensory aberrations.11–13 
QST measures responses to sensory stimuli and can be used 
to assess somatosensory system function,11,12 the measure-
ment of the altered peripheral and/or central pain sensitiv-
ity,14–16 and descending pain modulation.17,18 QST is thought 
to offer greater precision and reliability when assessing 
somatosensory system functionality than a standard BSE19,20 
because of the use of controlled automated devices. There 
is evidence that QST improves the diagnostic process 
of patients with pain, and that it may be valuable when 
monitoring for a specific anti-neuropathic treatment.21,22 
Moreover, an altered pain modulation can be assessed on 
the basis of signs and symptoms of peripheral and central 
sensitization17,23–25 and by the use of conditioned pain 
modulation (CPM).19,26 CPM is a physiological phenomenon 
that can be used to assess the quality of the endogenous 
pain inhibitory pathway, also known as the “pain inhibits 
pain” phenomena.27 The Nijmegen–Aalborg screening QST 
(NASQ)15,16,24,28 measures pain and central pain processing 
under standardized conditions using defined stimuli and 
experienced intensity ratings. There is no “gold standard” 
for the diagnosis of NePC, and the association between 
NePC and BSE/NASQ has not yet been fully evaluated. 
There is a need for studies to more objectively identify the 
presence of an NePC and to assess the diagnostic accuracy 
of BSE and NASQ for NePC.5
The objective of this study was to assess the potential 
association between clinically diagnosed absent or present 
NePC and BSE and NASQ in patients with chronic (≥3 
months) low back and leg pain (LBLP) or with neck shoulder 
arm pain (NSAP) radiating into the leg(s) or arm(s), or in 
patients with chronic pain due to suspected peripheral nerve 
damage (sPND).
Methods
This study is based on a cross-sectional, observational research 
design to generate new insights into the clinical assessment of 
NePC. It is a sub-analysis of a study approved by the medical 
and ethical review board Committee on Research Involving 
Human Subjects, region Arnhem-Nijmegen, Nijmegen, the 
Netherlands, dossier number: 2008/348; NL 25343.091.08.
In the original study conducted between October 2009 
and June 2013, we validated the Dutch PainDETECT29 and 
the DN4.30,31 The PainDETECT32 and the DN433 were both 
developed to screen for the presence of neuropathic pain. The 
patient self-administered PainDETECT is a simple screening 
tool with no need for physical examination. The instrument 
consists of one item about the pain course pattern, one about 
radiating pain, and seven questions about the gradation of pain. 
The clinician-administered DN4 consists of a total of 10 items 
with yes/no answers. It is divided into two questions (symp-
toms) and two physical examination tests (signs). The two sign 
items were incorporated in the sensory examination part of the 
standardized assessment form.28 The protocol was registered in 
the Dutch National Trial Register: NTR 3030 and published by 
Timmerman et al.28 Patients provided written informed consent 
after screening, but before participation in the study.
Participants
We recruited patients as part of the Dutch validation studies 
concerning the PainDETECT and the DN4. Inclusion criteria 
were male and female adult patients aged over 18 years with 
chronic (≥3 months) LBLP or NSAP, or patients with chronic 
pain due to sPND. We excluded patients suspected for or diag-
nosed with malignancy; compression fractures; patients with 
diffuse pains such as fibromyalgia or ankylosing spondylitis; 
severe mental illness; chronic alcoholism or substance abuse; 
inability to fill in the questionnaire adequately; or incapable 
of understanding the Dutch language.
Pain classification
Classification of patients’ pain was based on the NeuPSIG 
guidelines on neuropathic pain assessment.6 Pain classifica-
tion was performed consecutively but blinded for the outcome 
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on the same patient independently by two physicians working 
in different compositions, and then categorized into three 
groups: “absent NePC”, “present NePC” where both physi-
cians were in agreement, or “undetermined NePC” in cases 
where they did not agree. A full medical history and clinical 
examination including sensory BSE was taken6,7,21,28,34 and 
considered as the gold standard for NePC diagnosis.
Bedside examination
Multicenter recruitment took place in the Netherlands in 
three academic pain centers and in four non-academic pain 
centers. A standardized BSE28 was independently performed 
by two physicians during the validation study for the two 
neuropathic pain screening tools. Prior to the study, the 
physicians were trained in the standardized evaluation of 
patients with chronic pain using specific modalities such as 
touch, pin prick, pressure, cold, heat, vibration, and temporal 
summation. The location indicated by the patient as having 
maximum pain was compared with the mirrored location on 
the contralateral side. When the pain had a double-sided char-
acter, a location without pain but as close as possible to the 
original mirror site was tested for comparison. Patients were 
asked the following: 1) is a sensation present? 2) is the sensa-
tion unpleasant? or 3) is the sensation painful? (all scored as 
yes, no, or unclear) The outcome was noted by the physician 
on the standardized assessment form.28 The following tests 
were performed consecutively on each patient independently 
by two physicians: 1) mechanical static allodynia via blunt 
pressure with a finger at a force that normally does not evoke 
pain; 2) dynamic mechanical allodynia via stroking the skin 
with a Soft Brush (SENSElab™, Brush-05, Somedic AB, 
Hörby, Sweden), 2a) one movement of 1–2 centimeter and 
2b) three movements of 1–2 centimeters (wind-up response); 
3) mechanical pinprick allodynia via touch of the skin with 
3a) a plastic safety pin and 3b) a Von Frey hair (TOUCH 
TEST®, 5.07, 10.0 g, North Coast Medical Inc., Gilroy, CA, 
USA); 4) heat allodynia by use of TipTherm® (TipTherm, 
Brüggen, Germany) in a baby-bottle warmer (ISI mini Baby 
Bottle Warmer, Assen, the Netherlands) set at 45 degrees 
Celsius; 5) cold allodynia with an ice cube placed on the 
skin for 2 seconds; and 6) vibration with a tuning fork (128 
Hz; Medipharchem, Wormerveer, the Netherlands) applied 
to joint, bone, or soft tissue in the region of the pain.
nijmegen–aalborg screening QsT
Patients for the additional NASQ part of the study were 
recruited in one academic pain center and two non-academic 
pain centers. After screening in the clinical department, 
patients were asked to participate. The NASQ was performed 
in a random sub-sample of 20% of the patient population 
(LBLP, NSAP, and sPND) by a trained and experienced 
researcher (HT).28 The NASQ paradigm15,16,24,28 was used 
as screening protocol. The NASQ screens for changes in 
pain processing based on a systematic mechanism-oriented 
approach.16 It maps pain sensitivity at multiple sites by 
measuring the responses (ie, painful sensations) evoked by 
mechanical and electrical non-invasive stimuli, and mea-
sures the patient’s capacity to modulate pain using the CPM. 
Instructions were standardized and read to each patient from 
an instruction sheet.
Pressure pain threshold (PPT) test
A pressure algometer (Somedic AB) was used to measure 
PPTs bilaterally at each location, expressed in kilo Pascal: 
thenar (middle part), musculus trapezius pars median (middle 
part), musculus rectus femoris (15 cm above patella), and 
musculus abductor hallucis (middle part). In addition to the 
analysis with an average value over these eight measurement 
points, we performed additional analyses in the four central 
measurement points: musculus trapezius pars median (both 
sides) and musculus rectus femoral (both sides), and the four 
peripheral measurement points: thenar (both sides) and m. 
abductor hallucis (both sides).
electrical pain thresholds
The QST-3 device (JNI Biomedical ApS, Klarup, Denmark) 
was used to measure electrical pain thresholds (EPTs) on 
the left and right body side. Measurement locations were 
the musculus trapezius pars median (middle part) and the 
musculus rectus femoris (20 cm above patella). Thresholds 
were assessed and expressed in milli-Ampère. EPTs were 
measured as electrical pain detection threshold (EPDT) 
when the current started to feel pain, and as electrical pain 
tolerance threshold (EPTT) when the current was as high as 
the patient could tolerate.
cPM response
We assessed CPM17,27 via the PPT (CPMp) and the EPT 
(CPMe) on the m. rectus femoris contralateral to the dominant 
hand. The noxious stimulus (conditioning stimulation) was 
to immerse the dominant hand to the wrist in a bucket filled 
with water and ice cubes (ice water bucket [IWB] test).25 The 
patient was instructed to “keep the hand in the water for as 
long as possible, until the moment that the sensation becomes 
unbearable and you want to stop directly”. Pain was recorded 
every 10 seconds on the numeric rating scale. The duration 
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of the immersion (with a maximum of 180 seconds) was 
recorded and the pain intensity at the end of the immersion 
was also registered. The PPT and the EPT were then assessed 
again on the contralateral m. rectus femoris. The response 
was calculated by subtracting the outcome of the pre-mea-
surement from the outcome of the post-measurement. The 
CPM values were calculated using the following formulas: 
 CPMp=([PPT
post
 − PPT
pre
]/PPT
pre
) * 100
 CPMe=([EPT
post
 − EPT
pre
]/EPT
pre
) * 100
CPM was regarded as “positive” when the outcome of the 
calculation was equal or higher than zero and negative when 
it was below zero.
Data
All data were collected on paper from the patients and the 
physicians and stored at Radboudumc, Nijmegen, the Neth-
erlands. Data management and monitoring were performed 
using MACRO (MACRO, version 4.1.1.3720, InferMed, 
London, UK). Data analysis and statistics were performed 
using Statistical Package for the Social Sciences (SPSS ver-
sion 20.0, SPSS Inc., Chicago, IL, USA).
statistical methods
Qualitative variables are presented as frequencies and per-
centages. Quantitative variables are presented as mean and 
SD or as median and interquartile range. The chi-square test 
was used to test for significant differences between nominal 
outcome data. Cramér’s V was used as a measure of associa-
tion between two nominal variables, giving a value between 0 
and 1. Mann–Whitney U-test was used to test the differences 
between present and absent NePC. Kruskal–Wallis test was 
used to study differences between the three (absent NePC, 
present NePC, and undetermined) groups. We used Cohen’s 
Kappa and the percentage of pair wise agreement to determine 
the agreement between the BSE between the patient’s first 
and second assessment. A two-tailed p-value below 0.05 was 
considered statistically significant.
Results
In total, 330 patients with chronic LBLP, NSAP, or sPND 
were assessed for eligibility. Two patients did not provide 
informed consent prior to inclusion in the study. Thirty-seven 
patients were excluded because of not meeting the inclusion 
and exclusion criteria (n=13); not returning the baseline 
questionnaires (n=16), and missing pain classification by 
one physician (n=5) or both physicians (n=3).
BSE was performed in this study in 291 patients by 62 
different physicians from seven hospitals. The present NePC 
group (n=170) consisted of 75 patients with LBLP, 23 patients 
with NSAP, and 72 patients with sPND. The absent NePC 
group (n=58) consisted of 28 patients with LBLP, 18 patients 
with NSAP, and 12 patients with sPND. For the undetermined 
group (n=63), the numbers were 29, 10, and 24, respectively 
(see Figure 1 and Table 1).
The NASQ was performed in a total of 69 patients. 
Patients were excluded after the NASQ measurements were 
made: not fulfilling the inclusion and exclusion criteria (n=9) 
or a missing assessment by a second physician (n=2). Finally, 
a total of 58 patients (56 Dutch natives, 1 German native, 
and 1 of Chinese/Indonesian origin) were included in the 
analysis: 25 with LBLP, 25 with NSAP, and 8 with sPND. 
After NePC assessment by the physicians, 16 patients were 
classified as absent NePC, 29 with present NePC, and 13 
patients with an undetermined outcome. The absent NePC 
group, present NePC group, and undetermined group had 
4, 14, and 7 patients with LBLP; 12, 7, and 5 patients with 
NSAP; and 0, 7, and 1 patient(s) with sPND, respectively 
(see Figure 1 and Table 1).
In Tables 2 and S1, we have shown the outcome of the 
BSE based on the inter-physician agreement on the exis-
tence of an NePC. In the first assessment by the physician, 
the answers on the question “is there a sensation (yes, no, 
unclear) during testing for heat, cold, touch (brush 3 times), 
and pricking (both safety pin and von Frey hair)” were sig-
nificantly lower (p<0.05) for yes in the group with present 
NePC compared to the absent NePC group. In the second 
assessment, the scores for the question “is there a sensation 
(yes, no, unclear) of heat, cold, touch, (only brush 1 time), 
and pricking (von Frey hair only)” were significantly lower 
(p<0.05) for yes in the group with present NePC with a lower 
percentage of “yes” compared to the absent NePC. The scores 
for the questions “is the touch with a finger unpleasant?” 
and “is touch with a brush unpleasant?” were higher for the 
second assessment for the group with present NePC (p=0.049 
and p=0.006, respectively). “Painful for touch with a finger” 
was more common in patients with present NePC (p=0.026) 
in the second assessment. “Wind-up” was more common in 
patients with present NePC compared to the patients with 
absent NePC (first assessment p=0.056; second assessment 
p=0.029). In Table S1, we have shown the outcome of the 
BSE based on the inter-physician agreement for the occur-
rence of NePC for patients with LBLP, NSAP, and sPND.
The outcomes of the NASQ measurements related to phy-
sician agreement for the existence of NePC are presented in 
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Table 3. No significant difference was detected for pressure, 
EPDT, EPTT, and duration of submerging the hand in the 
IWB between the absent, present, and undetermined NePC 
groups. We found no congruency between the CPMp and 
the CPMe. When basing the CPM classification on pressure 
values, the significance disappeared for the outcome of the 
CPM test based on electricity values (response p=0.440, 
CPM-value p=0.374). This was also true when the CPM 
electricity test outcome was used to analyze the response 
and CPM value for pressure (p=0.728 and p=0.810, respec-
tively). Moreover, in the IWB test, we found no significant 
differences regarding the duration (latency) of submerging 
the hand between the positive and negative CPM test for 
both the pressure and electricity conditions (p=0.120 and 
p=0.711, respectively).
Discussion
The aim of this study was to assess the potential association 
between a clinically diagnosed absent or present NePC, 
BSE, and NASQ in patients with chronic pain. BSE revealed 
minor differences, with a low association between patients 
with present NePC and patients with absent NePC following 
independent clinical NePC assessment by two independent 
physicians, while none were found with NASQ.
Bedside examination
We used BSE based on mechanical and thermal testing 
procedures, performed by two physicians independently and 
blinded for the results of the other.28 The added value of BSE 
is that it gives insights into the pathology and the localiza-
tion of the nerve lesion or disease causing the pain.6,7,35,36 
Figure 1 Flow diagram for the performance of the Bse and nasQ in patients with chronic pain with respect to the physicians’ assessment.
Notes: n, number of patients in analysis; Present nePc, nePc is present; Undetermined, both physicians disagree with each other about the presence of a nePc; absent 
nePc, no nePc is present.
Abbreviations: lBlP, low back and leg pain; nsaP, neck shoulder arm pain; sPnD, suspected peripheral nerve damage; Bse, bedside examination; nePc, neuropathic pain 
component; nasQ, nijmegen– aalborg screening quantitative sensory testing.
Patients with chronic pain due to LBLP, NSAP, or
sPND assessed for eligibility 
No informed consent
n=2
Classification of NePC by physicians’ assessment
n=328
Performance of BSE (excluded with reasons n=37)
n=291
Present NePC
n=170
Undetermined
n=63
Absent NePC
n=58
Performance of NASQ (excluded with reasons n=11)
n=58
Present NePC
n=29
Undetermined
n=13
Absent NePC
n=16
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The BSE results showed statistical significant differences 
between patients with absent NePC and patients with present 
NePC. BSE revealed that the sensation of heat, cold, wind-up 
response (with a brush, three times), pricking with a safety 
pin, and pricking with a von Frey hair was less common in 
patients with a present NePC than in those with an absent 
NePC. In addition, wind-up response occurred more often in 
patients with present NePC than in those with absent NePC.
screening QsT
We used the NASQ to assess the altered pain processing, 
including changes in function of endogenous pain modulation 
as a secondary test battery.15,28 The NASQ test protocol has 
standardized instructions, an important prerequisite to ensure 
reliability of the measurements.20,37 We found no differences 
between patients with absent and present NePC regarding 
PPTs, electrical pain (tolerance) thresholds, and CPM out-
comes (number of positive and negative CPM outcomes, 
the response, the CPM value, and the latency times when 
submerging the hand in ice water). Granovsky38 reported 
that patients with chronic neuropathic pain express a less 
efficient (negative) CPM. In our study, we could not confirm 
this when comparing patients with LBLP, NSAP, or sPND 
with and without NePC. As suggested by Graven-Nielsen and 
Arendt-Nielsen,39 lower PPTs may be indicative for central 
sensitization. We also could not find any differences in the 
pain thresholds of patients with and without NePC. Moreover, 
a difference in CPM may also suggest a central dysfunction. 
However, based on our results, we cannot state that there are 
signs of central sensitization or altered central pain process-
ing as might be suspected because of lower pain thresholds 
for pressure pain or an impaired CPM, because we did not 
include age, sex, and education matched controls, which 
would be necessary to draw these higher level conclusions.
limitations
We would have preferred to use the German Research Net-
work on Neuropathic Pain (DFNS)11,12 to BSE because of 
the standardization of the complete test procedure (written 
test instructions, application of the test stimuli, and data 
analyses).12,40 However, due to time constraints in a patient 
care setting, it was not possible and preferable to use such a 
research test battery. Moreover, in simulating daily clinical 
practice, fulfilling the DFNS protocol is not applicable due 
Table 1 sociodemographic characteristics for the patients included in the Bse and the nasQ examination related to the physicians’ 
agreement for the existence of an nePc
Total group Absent NePC Present NePC p-value Undetermined NePC p-value
Bedside examination n (%)
Median (IQR)
(N=291)
n (%)
Median (IQR) 
(N=58)
n (%)
Median (IQR)
(N=170)
(N=228) n (%)
Median (IQR)
(N=63)
(N=291)
sex Male
Female
98 (34%)
193 (66%)
25 (43%)
33 (57%)
56 (33%)
114 (67%)
0.163a 17 (27%)
46 (73%)
0.164a
age (years) 57 (49;64) 57 (50;62) 57 (49;64) 0.935b 57 (49;67) 0.831c
BMi (kg/m2) 26 (24;30) 26 (23;30) 26 (24;30) 0.943b 27 (24;30) 0.688c
Pain
(nRs; 0–10)
current pain
Worst pain
average pain
5 (3;7)
8 (6;9)
6 (4;7)
5 (3;7)
8 (5;9)
6 (3.5;7)
6 (3;7)
8 (7;9)
6 (5;8)
0.577b
0.371b
0.233b
4 (1;7)
7 (5;8)
6 (3;7)
0.084c
0.053c
0.018c
Duration of pain (months) 36 (18;60) 48 (18;60) 31 (18;60) 0.445b 36 (14;60) 0.733b
Quantitative sensory 
testing
n (%)
Median (IQR)
(N=58)
n (%)
Median (IQR) 
(N=16)
n (%)
Median (IQR)
(N=29)
(N=45) n (%)
Median (IQR)
(N=13)
(N=58)
sex Male
Female
31 (53%)
27 (47%)
9 (56%)
7 (44%)
15 (52%)
14 (48%)
0.771a 7 (54%)
6 (46%)
0.958a
age (years) 58 (52;64) 59 (52;63) 58 (52;64) 0.669b 56 (52;65) 0.906c
BMi (kg/m2) 27 (25;31) 26 (23;30) 27 (25;31) 0.674b 28 (25;32) 0.908c
Pain
(nRs; 0–10)
current pain
Worst pain
average pain
6 (5;7)
8 (7;9)
7 (6;7)
6 (5;7)
8 (8;9)
7 (6;7)
6 (5;7)
8 (7;9)
7 (6;8)
0.887b
0.740b
0.424b
5 (2;8)
8 (8;9)
7 (5;8)
0.613c
0.706c
0.567c
Duration of pain (months) 36 (18;78) 52 (30;227) 26 (18;81) 0.069b 24 (12;57) 0.104c
Notes: Classification for the existence of NePC is based on physicians’ assessment of the patients. Absent NePC, no NePC is present; Present NePC, NePC is present; 
p-value, value for significant difference between groups (p≤0.05); n, total number of patients in analysis; achi-square test; bMann–Whitney U-test; cKruskal–Wallis test. Bold 
values are statistically significant (p≤0.05).
Abbreviations: Bse, bedside examination; nasQ, nijmegen–aalborg screening quantitative sensory testing; nePc, neuropathic pain component; BMi, body mass index; 
nRs, numeric rating scale; median (iQR), median with interquartile range (25%–75%).
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to instrument availability and the associated costs in all par-
ticipating sites. BSE as used in our study is easy to learn (one 
training session before execution of the study) and to carry 
out in daily clinical practice. Another strength of the study 
is that we included a range of locations and a large group 
of patients with chronic pain arising from different origins, 
which is comparable to patients in a daily clinical (pain) 
practice. A limitation of the BSE examination is that we only 
used the question “Is there a sensation?” This may have led 
to a lower estimation of the outcomes because the patients 
and/or physicians may have interpreted the question was only 
being related to the presence of hypoesthesia, hypoalgesia, or 
analgesia (answer “no”: negative signs) rather than assessing 
the presence of hyperalgesia or allodynia positively (answer 
“yes”). In a following study, we will change this to a more 
open question that can be interpreted both ways. We did not 
use verbal standardized instructions, although all participat-
ing professionals were trained in a standardized way and so 
this is another possible limitation of our BSE method. This 
may have led to differences in the questioning by the physi-
cians, thereby influencing the patients’ answers and the test 
outcome. The order of the BSE tests was not randomized and 
so there may be an order effect resulting from the previously 
performed test. Moreover, both physicians tested the same 
Table 2 Bedside examination outcome based on inter-physician (a–B) agreement on the presence of an nePc
First assessment Second assessment Agreement  
between  
physicians
N total Absent  
NePC
Present  
NePC
p-value V N total Absent  
NePC
Present  
NePC
p-value V
n % n % n % n % K PA (%)
Touch (finger)
sensation 290 58 95 169 95 0.964 0.003 289 58 97 168 96 0.965 0.003 0.177 93.3
Unpleasant 288 57 35 168 45 0.181 0.089 289 58 33 168 48 0.049 0.131 0.378 69.5
Painful 286 57 28 167 37 0.215 0.083 288 57 25 168 41 0.026 0.149 0.315 68.8
Heat
sensation 283 57 91 166 68 0.001 0.230 287 57 91 167 66 0.000 0.247 0.435 77.6
Unpleasant 283 57 16 166 16 0.707 0.056 287 57 16 167 21 0.396 0.057 0.319 79.9
Painful 283 57 7 166 9 0.626 0.065 287 57 12 167 14 0.775 0.019 0.258 90.0
Cold
sensation 275 55 93 165 75 0.016 0.194 284 58 93 168 75 0.003 0.196 0.320 77.6
Unpleasant 274 55 2 164 12 0.052 0.164 284 58 7 168 11 0.338 0.064 0.333 87.6
Painful 273 54 0 164 5 0.178 0.126 284 58 2 168 6 0.197 0.086 0.477 95.4
Touch (brush 1 time)
sensation 288 58 93 167 81 0.104 0.142 286 57 93 167 79 0.017 0.160 0.264 79.6
Unpleasant 288 58 2 167 7 0.156 0.095 287 57 2 168 7 0.132 0.100 0.384 93.7
Painful 288 58 0 167 2 0.234 0.079 287 57 0 168 4 0.148 0.096 0.387 97.3
Touch (brush 3 times)
sensation 290 58 97 169 85 0.021 0.153 289 58 91 169 80 0.055 0.127 0.303 82.7
Unpleasant 291 58 2 170 7 0.130 0.100 290 58 0 169 12 0.006 0.182 0.197 89.4
Painful 291 58 0 170 2 0.308 0.067 290 58 0 169 5 0.092 0.112 0.351 96.9
Wind-up 284 56 0 167 8 0.056 0.161 276 50 0 164 12 0.029 0.182 0.188 87.1
Pricking (safety pin)
sensation 289 58 95 168 79 0.006 0.183 290 58 91 169 82 0.080 0.116 0.240 79.6
Unpleasant 290 58 19 169 31 0.180 0.123 290 58 24 169 31 0.298 0.069 0.357 73.4
Painful 290 58 10 169 20 0.227 0.114 290 58 16 169 21 0.388 0.057 0.286 78.3
Pricking (von Frey hair)
sensation 289 58 91 168 68 0.003 0.230 288 57 91 169 68 0.001 0.229 0.455 79.0
Unpleasant 289 58 7 168 14 0.228 0.114 288 58 16 167 20 0.475 0.048 0.329 81.6
Painful 289 58 3 168 7 0.473 0.081 288 58 12 167 10 0.590 0.036 0.402 90.6
Vibration
sensation 291 58 79 170 69 0.060 0.157 288 58 81 167 66 0.089 0.147 0.358 73.3
Unpleasant 290 57 5 170 10 0.528 0.075 290 58 5 169 11 0.275 0.107 0.225 85.4
Painful 291 58 3 170 8 0.517 0.076 290 58 0 169 7 0.114 0.138 0.435 93.0
Notes: Classification of the presence of NePC is based on physicians’ assessment of the patient. n, the number of patients; %, the percentage of positive answers (yes) on 
the questions: sensation: is there a sensation?; Unpleasant: is the sensation unpleasant?; Painful: is the sensation painful?; p-value=p-value for statistical significant difference 
between groups (outcome of chi-square test, p≤ 0.05). Bold values are statistically significant (p≤0.05).
Abbreviation: nePc, neuropathic pain component; V, value of cramér’s V; K, Kappa value; Pa, percentage of agreement.
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patient directly following each other. Although the second 
physician was not aware of the first results, this may have also 
influenced our results. Furthermore, there was no correction 
for multiple testing while several statistical analyses were 
performed. Because of this, the results must be interpreted 
with caution.
Another possible limitation is the fact that we only 
included a small group of patients with chronic pain mea-
sured via NASQ; 8 patients with sPND. This may have 
affected our outcome because they have a different disease 
origin compared to patients with LBLP or NSAP. For future 
NASQ research, we would suggest collecting normative 
data preferably matched for age, sex, and education level. 
With these data, the value of NASQ for clinical monitoring 
disease progression and the response of individual patients 
on treatment can be evaluated.
Conclusion
Using a standardized BSE to assess sensory dysfunction 
indicating the presence or absence of an NePC appears to 
be preferable compared to the NASQ paradigm in patients 
Table 3 Patient nasQ values related to physicians’ agreement for the presence of an nePc
Total group 
 
Congruent 
outcome by the 
physicians
Absent NePC 
 
Present NePC 
 
p-value
N N N N
Pressure
(kPa)
summed total
central
Peripheral
39
56
39
872 (516;1117)
866 (542;1068)
794 (526;1084)
30
43
30
858 (506;1125)
872 (545;1058)
793 (516;1095)
5
15
5
846 (729;1086)
892 (600;989)
800 (701;1066)
25
28
25
929 (465;1132)
793 (435;1068)
787 (488;1106)
0.718b
0.558b
0.676b
CPM Positive
negative
no change 
Response
cPM value
23
17
40
40
58%
43%
131 (−13;225)
7.2 (−14;25)
19
12
31
31
61%
39%
109 (3;221)
7 (−18;23)
3
2
5
5
60%
40%
13 (−31;176)
3 (−19;16)
16
10
26
26
62%
39%
155 (24;222)
8.0 (−16;34)
0.948a
0.259b
0.591b
EPDT (ma) Total mean 53 11 (7;17) 42 12 (8;17) 16 11 (6;20) 26 12 (8;17) 0.969b
CPM Positive
negative
no change 
Response
cPM value
13
3
16
16
81%
19%
0.8 (0.03;4)
7.7 (0.3;30)
10
2
13
12
12
40%
8%
52%
2 (0.2;5)
20 (3;34)
8
2
10
10
80%
20%
2 (−0.05;4.0)
15 (−0.2;37)
2
0
2
2
100%
---c
3 (0.4;---)c
26 (18;---)c
0.488a
0.747b
0.667b
EPTT (ma) Total mean 25 10 (8;22) 19 13 (8;23) 3 13 (10;---)c 16 12 (8;22) 0.314b
CPM Positive
negative
no change 
Response
cPM value
17
8
25
25
68%
32%
0.5 (−0.2;2)
7 (−2;16)
13
6
19
19
68%
32%
0.5(−0.2;2)
7 (−2;17)
3
0
3
3
100%
---c
2 (1;---)c
12 (9;---)c
10
6
16
16
63%
38%
0.4 (−0.3;2)
4.8 (−3;16)
0.200a
0.117b
0.219b
IWB test latency (s) 41 20 (10;170) 32 40 (10;180) 5 40 (10;170) 27 40 (10;180) 0.960b
Notes: Classification of presence of NePC is based on physicians’ assessment of the patients. Absent, NePC is absent; Present, NePC is present; Undetermined, both 
physicians disagree with each other about the existence of an nePc; n, number of patients in the analysis; cPM > ±10%: patients included in the analysis with a cPM of more 
than 10% difference from zero. achi-square test; bMann–Whitney U-test. p≤0.05 is considered statistically significant; cdue to the low number of patients in the analysis, iQR 
is not given in the 75% range.
Abbreviations: nasQ, nijmegen–aalborg screening quantitative sensory testing; nePc, neuropathic pain component; cPM, conditioned pain modulation; ePDT, electrical 
pain detection threshold; ePTT, electrical pain tolerance threshold; iWB, ice water bucket; iQR, interquartile range.
with chronic pain. However, further development of both 
assessments is desirable. The BSE should be adapted to 
detect sensory differences between absent and present NePC; 
the NASQ paradigm should be able to measure altered pain 
processing and endogenous pain modulation in patients with 
chronic pain due to present or absent NePC. We postulate 
that this will lead to a greater contribution to the assessment 
of neuropathic components of patients’ pain.
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Supplementary material
Table S1 Bedside examination outcome based on inter physician agreement on the presence of an nePc for the total group and for 
patients with lBlP, nsaP, or sPnD separately
First assessment Second assessment Agreement  
between  
physicians
N total Absent  
NePC
Present  
NePC
p-value V N total Absent  
NePC
Present  
NePC
p-value V
n % n % n % n % K PA (%)
Touch (finger)
sensation Total 290 58 95 169 95 0.964 0.003 289 58 97 168 96 0.965 0.003 0.177 93.3
lBlP 131 28 100 74 99 0.536 0.061 132 28 100 75 96 0.283 0.106
−0.015 96.0
nsaP 51 18 89 23 91 0.796 0.040 50 18 94 22 95 0.884 0.023 0.787 97.5
sPnD 108 12 92 72 92 1.000 0.000 107 12 92 71 97 0.344 0.104
−0.053 91.3
Unpleasant Total 288 57 35 168 45 0.181 0.089 289 58 33 168 48 0.049 0.131 0.378 69.5
lBlP 130 27 22 74 30 0.456 0.074 132 28 25 75 28 0.761 0.030 0.242 70.3
nsaP 51 18 44 23 44 0.951 0.010 50 18 33 22 45 0.436 0.123 0.388 70.0
sPnD 107 12 50 71 62 0.433 0.086 107 12 50 71 69 0.198 0.141 0.318 68.3
Painful Total 286 57 28 167 37 0.215 0.083 288 57 25 168 41 0.026 0.149 0.315 68.8
lBlP 130 27 19 74 22 0.734 0.034 132 28 18 75 43 0.425 0.079 0.202 73.3
nsaP 51 18 33 23 44 0.509 0.103 50 18 28 22 41 0.386 0.137 0.297 67.5
sPnD 105 12 42 70 51 0.532 0.069 106 11 36 71 58 0.185 0.146 0.275 63.8
heat
sensation Total 283 57 91 166 68 0.001 0.230 287 57 91 167 66 0.000 0.247 0.435 77.6
lBlP 127 27 96 71 69 0.004 0.288 131 27 96 75 68 0.003 0.290 0.579 84.5
nsaP 48 18 89 23 74 0.230 0.188 50 18 100 22 86 0.103 0.258 0.286 82.5
sPnD 108 12 83 72 65 0.215 0.135 106 12 67 70 57 0.536 0.068 0.301 67.1
Unpleasant Total 283 57 16 166 16 0.707 0.056 287 57 16 167 21 0.396 0.057 0.319 79.9
lBlP 127 27 22 71 8 0.153 0.196 131 27 19 75 13 0.514 0.065 0.117 79.4
nsaP 48 18 6 23 9 0.702 0.060 50 18 6 22 18 0.230 0.190 0.231 87.5
sPnD 108 12 17 72 25 0.742 0.084 106 12 25 70 30 0.725 0.039 0.424 76.8
Painful Total 283 57 7 166 9 0.626 0.065 287 57 12 167 14 0.775 0.019 0.258 90.0
lBlP 127 27 7 71 3 0.494 0.120 131 27 11 75 8 0.625 0.048
−0.057 87.6
nsaP 48 18 6 23 9 0.702 0.060 50 18 6 22 14 0.397 0.134 0.286 90.0
sPnD 108 12 8 72 15 0.741 0.084 106 12 25 70 20 0.693 0.044 0.355 80.5
cold
sensation Total 275 55 93 165 75 0.016 0.194 284 58 93 168 75 0.003 0.196 0.320 77.6
lBlP 130 28 96 74 80 0.038 0.205 131 28 96 75 79 0.031 0.213 0.458 85.3
nsaP 43 15 87 22 86 0.979 0.004 50 18 100 22 95 0.360 0.145 0.302 89.2
sPnD 102 12 92 69 65 0.186 0.204 103 12 75 71 65 0.489 0.076 0.148 62.5
Unpleasant Total 274 55 2 164 12 0.052 0.164 284 58 7 168 11 0.338 0.064 0.333 87.6
lBlP 129 28 4 73 10 0.489 0.119 131 28 7 75 5 0.727 0.034 0.357 91.1
nsaP 43 15 0 22 9 0.230 0.197 50 18 0 22 18 0.057 0.302 0.641 94.6
sPnD 102 12 0 69 16 0.294 0.174 103 12 17 71 15 0.918 0.011 0.217 80.0
Painful Total 273 54 0 164 5 0.178 0.126 284 58 2 168 6 0.197 0.086 0.477 95.4
lBlP 129 28 0 73 0 0.534 0.062 131 28 4 75 1 0.464 0.072
−0.007 97.0
nsaP 42 14 0 22 5 0.418 0.135 50 18 0 22 14 0.103 0.258 0.478 94.4
sPnD 102 12 0 69 10 0.462 0.138 103 12 0 71 8 0.296 0.115 0.582 93.8
Touch (brush 1 time)
sensation Total 288 58 93 167 81 0.104 0.142 286 57 93 167 79 0.017 0.160 0.264 79.6
lBlP 130 28 100 73 90 0.089 0.169 132 28 100 75 88 0.055 0.189 0.187 88.1
nsaP 51 18 89 23 96 0.409 0.129 48 17 100 22 86 0.113 0.254 0.278 89.7
sPnD 107 12 83 71 68 0.533 0.123 106 12 67 70 67 0.974 0.004 0.178 64.2
Unpleasant Total 288 58 2 167 7 0.156 0.095 287 57 2 168 7 0.132 0.100 0.384 93.7
lBlP 130 28 4 73 6 0.826 0.022 132 28 0 75 3 0.383 0.086 0.385 97.0
nsaP 51 18 0 23 9 0.200 0.200 48 17 0 22 18 0.063 0.297 0.374 62.3
sPnD 107 12 0 71 10 0.256 0.125 106 12 8 71 8 0.989 0.001 0.375 90.2
(Continued)
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Bse and nasQ in patients with and without nePc
First assessment Second assessment Agreement  
between  
physicians
N total Absent  
NePC
Present  
NePC
p-value V N total Absent  
NePC
Present  
NePC
p-value V
n % n % n % n % K PA (%)
Painful Total 288 58 0 167 2 0.234 0.079 287 57 0 168 4 0.148 0.096 0.387 97.3
lBlP 130 28 0 73 1 0.534 0.062 132 28 0 75 3 0.383 0.086
−0.013 97.0
nsaP 51 18 0 23 0 --- --- 48 17 0 22 5 0.373 0.143 0.000 97.4
sPnD 107 12 0 71 4 0.468 0.080 107 12 0 71 4 0.468 0.080 0.654 97.6
Touch (brush 3 times)
sensation Total 290 58 97 169 85 0.021 0.153 289 58 91 169 80 0.055 0.127 0.303 82.7
lBlP 132 28 100 75 96 0.283 0.106 132 28 100 75 93 0.161 0.138 0.222 94.2
nsaP 51 18 89 23 96 0.409 0.129 50 18 100 22 86 0.103 0.258 0.279 90.0
sPnD 107 12 100 71 70 0.029 0.239 107 12 58 72 65 0.642 0.051 0.190 65.1
Unpleasant Total 291 58 2 170 7 0.130 0.100 290 58 0 169 12 0.006 0.182 0.197 89.4
lBlP 132 28 4 75 5 0.711 0.036 132 28 0 75 8 0.123 0.152 0.136 91.3
nsaP 51 18 0 23 87 0.200 0.200 50 18 0 22 23 0.031 0.342 0.304 90.0
sPnD 108 12 0 72 8 0.299 0.113 108 12 0 72 13 0.195 0.141 0.198 86.9
Painful Total 291 58 0 170 2 0.308 0.067 290 58 0 169 5 0.092 0.112 0.351 96.9
lBlP 132 28 0 75 3 0.383 0.086 132 20 0 75 4 0.283 0.106 0.386 97.1
nsaP 51 18 0 23 0 --- --- 50 18 0 22 5 0.360 0.145 0.000 97.5
sPnD 108 12 0 72 1 0.681 0.045 108 12 0 72 6 0.403 0.091 0.388 96.4
Wind-up Total 284 56 0 167 8 0.056 0.161 276 50 0 164 12 0.029 0.182 0.188 87.1
lBlP 131 28 0 75 7 0.304 0.152 125 26 0 71 7 0.310 0.155 0.296 91.8
nsaP 48 16 0 22 9 0.215 0.201 44 12 0 22 5 0.290 0.270 0.145 87.1
sPnD 105 12 0 70 10 0.468 0.136 107 12 0 71 15 0.143 0.161 0.116 81.5
Pricking (safety pin)
sensation Total 289 58 95 168 79 0.006 0.183 290 58 91 169 82 0.080 0.116 0.240 79.6
lBlP 132 28 100 75 85 0.032 0.211 132 28 100 75 92 0.123 0.152 0.046 85.4
nsaP 51 18 94 23 91 0.702 0.060 50 18 100 22 95 0.360 0.145 0.481 95.0
sPnD 106 12 25 71 35 0.489 0.079 108 12 58 72 67 0.574 0.061 0.176 64.6
Unpleasant Total 290 58 19 169 31 0.180 0.123 290 58 24 169 31 0.298 0.069 0.357 73.4
lBlP 132 28 21 75 31 0.519 0.113 132 28 32 75 32 0.989 0.001 0.456 76.7
nsaP 51 18 11 23 17 0.572 0.088 50 18 11 22 32 0.119 0.247 0.106 72.5
sPnD 107 12 25 71 35 0.489 0.076 108 12 25 72 31 0.697 0.043 0.308 69.9
Painful Total 290 58 10 169 20 0.227 0.114 290 58 16 169 21 0.388 0.057 0.286 78.3
lBlP 132 28 14 75 15 0.826 0.061 132 28 18 75 17 0.950 0.006 0.265 79.6
nsaP 51 18 0 23 13 0.111 0.249 50 18 11 22 27 0.204 0.201 0.082 77.5
sPnD 107 12 17 71 27 0.457 0.082 108 12 17 72 22 0.664 0.047 0.364 77.1
Pricking (von Frey hair)
sensation Total 289 58 91 168 68 0.003 0.230 288 57 91 169 68 0.001 0.229 0.455 79.0
lBlP 132 28 96 75 82 0.045 0.245 132 28 96 75 75 0.013 0.245 0.291 77.7
nsaP 51 18 94 23 91 0.702 0.060 50 18 100 22 91 0.189 0.208 0.787 97.5
sPnD 106 12 75 70 54 0.180 0.148 106 11 64 72 54 0.556 0.065 0.423 71.6
Unpleasant Total 289 58 7 168 14 0.228 0.114 288 58 16 167 20 0.475 0.048 0.329 81.6
lBlP 132 28 4 75 16 0.353 0.142 131 28 18 74 14 0.580 0.055 0.171 81.4
nsaP 51 18 0 23 13 0.111 0.249 50 18 11 22 32 0.119 0.247 0.437 85.0
sPnD 106 12 25 70 17 0.752 0.083 107 12 17 71 23 0.648 0.050 0.410 80.2
Painful Total 289 58 3 168 7 0.473 0.081 288 58 12 167 10 0.590 0.036 0.402 90.6
lBlP 132 28 4 75 4 0.823 0.062 131 28 14 74 8 0.349 0.093 0.292 90.2
nsaP 51 18 0 23 8 0.111 0.249 50 18 6 22 14 0.397 0.134 0.531 92.5
sPnD 106 12 8 70 7 0.909 0.048 107 12 17 71 10 0.483 0.077 0.450 90.1
Vibration
sensation Total 291 58 79 170 69 0.060 0.157 288 58 81 167 66 0.089 0.147 0.358 73.3
lBlP 132 28 71 75 68 0.218 0.172 131 28 71 74 58 0.217 0.122 0.446 74.5
nsaP 51 18 89 23 78 0.369 0.140 50 18 94 22 91 0.673 0.067 0.136 82.5
sPnD 108 12 83 72 68 0.284 0.117 107 12 83 71 66 0.484 0.132 0.242 67.5
Table S1 (Continued)
(Continued)
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Timmerman et al
First assessment Second assessment Agreement  
between  
physicians
N total Absent  
NePC
Present  
NePC
p-value V N total Absent  
NePC
Present  
NePC
p-value V
n % n % n % n % K PA (%)
Unpleasant Total 290 57 5 170 10 0.528 0.075 290 58 5 169 11 0.275 0.107 0.225 85.4
lBlP 132 28 4 75 8 0.571 0.105 132 28 0 75 7 0.304 0.152 0.362 91.3
nsaP 50 17 6 23 9 0.738 0.053 50 18 6 22 23 0.130 0.239 0.133 87.2
sPnD 108 12 8 72 13 0.838 0.065 108 12 17 72 13 0.855 0.061 0.155 79.8
Painful Total 291 58 3 170 8 0.517 0.076 290 58 0 169 7 0.114 0.138 0.435 93.0
lBlP 132 28 4 75 9 0.720 0.080 132 28 0 75 3 0.562 0.106 0.380 94.2
nsaP 51 18 0 23 13 0.111 0.249 50 18 0 22 14 0.103 0.258 0.640 95.0
sPnD 108 12 8 72 8 0.919 0.045 108 12 0 72 8 0.299 0.113 0.381 90.5
Notes: Classification for the existence of NePC is based on the physicians’ assessment of the patient. n, the number of patients; %, the percentage of positive answers (yes) 
on the questions; sensation, is there a sensation?; Unpleasant, is the sensation unpleasant?; Painful, is the sensation painful?; p-value, p value for statistical significant difference 
between groups (outcome of chi-square test, p≤0.05). Bold values are statistically significant (p≤0.05).
Abbreviations: nePc, neuropathic pain component; lBlP, low back and leg pain; nsaP, neck shoulder arm pain; sPnD, suspected peripheral nerve damage; V, value of 
cramér’s V; K, Kappa value; Pa, percentage of agreement.
Table S1 (Continued)
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